



**Supplementary information, Fig. S1: The antiviral activity of dalbavancin against SARS-CoV-2 in vitro.** **a** Dalbavancin inhibits cytopathic effect (CPE) caused by SARS-CoV-2 infection in Vero-E6 cells. The bright field was used to evaluate CPE. Dalbavancin inhibited CPE and prevented Vero-E6 cell death after 72h post-infection with SARS-CoV-2. Scale bar, 25  $\mu$ m. **b** Inhibition of Cathepsin L activity by dalbavancin. CTSL (20  $\mu$ M, cathepsin L inhibitor I, MG-101) was used as a positive control. The mean  $\pm$  SD from at least three independent experiments with technical triplicates is shown. Statistical significance was measured by ANOVA compared with control group. **\*\*** $P < 0.01$ . **c** The 3D structure represents the binding site of dalbavancin on ACE2, point mutated residues (red) are affected the binding of dalbavancin to ACE2.